|Day Low/High||152.31 / 155.51|
|52 Wk Low/High||125.84 / 197.00|
- New data to address the treatment duration potential of first-in-class sustained release biodegradable implant -
In this day and age, companies must be 'disruptors' or get left in the dust.
- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
Jim Cramer's watching six stocks to determine when the selling will end.
Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.
David Tepper's Appaloosa LP renews calls for changes at the top.
Allergan wants Botox licenses for pediatric patients.
Applications Seek to Extend Use of BOTOX® for Patients 2 to 17 Years Old
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
-- Three acute pivotal studies did not meet their primary endpoint --
DUBLIN, March 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39 th Annual Health Care...
DUBLIN, March 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.
DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter: "While we appreciate the input of Appaloosa as we do all of our shareholders, we...
- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
I still believe it will be a big year for buyouts across the biotech industry.
DUBLIN, Feb. 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare...
Net income declines to EUR 253 million reflecting unfavorable market movements and other charges Underlying earnings decrease by 8% to EUR 1,010 million, as lower Retirement Plans earnings in the US more than offset business growth and higher margins in...
Aegon has set new medium-term financial targets with a focus on growing capital generation and dividends.
Shares of the Botox competitor could correct/consolidate after a recent surge.
Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.
Right now it feels as though everyone sees the obvious resistance and overbought situation.
Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.
Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.